CN110922382A - iso-Penicillium xanthone A from penicillium oxalicum and application in lymphoma - Google Patents
iso-Penicillium xanthone A from penicillium oxalicum and application in lymphoma Download PDFInfo
- Publication number
- CN110922382A CN110922382A CN201811474254.1A CN201811474254A CN110922382A CN 110922382 A CN110922382 A CN 110922382A CN 201811474254 A CN201811474254 A CN 201811474254A CN 110922382 A CN110922382 A CN 110922382A
- Authority
- CN
- China
- Prior art keywords
- penicillium
- lymphoma
- compound
- penicillium oxalicum
- xanthone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D311/86—Oxygen atoms, e.g. xanthones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to iso-Penicillium xanthone A derived from Penicillium oxalicum and its application in lymphoma. The compound is characterized by comprising the following structural characteristics:
Description
Technical Field
The invention relates to iso-Penicillium xanthone A derived from penicillium oxalicum and application thereof in lymphoma, belonging to the field of biological medicine.
Background
With the development of science and technology, the medical level of our medicine has been improved, but the incidence of cancer is on the rise, which is the second leading cause of death worldwide. Malignant Lymphoma (ML) is a general term for a group of malignant tumors originating from lymphohematopoietic system, and is a blood system with the fastest increasing incidence rate, the early symptoms of which are atypical, the individual differences of the first symptoms of which are large, and the lesions can occur anywhere in the body, which is called "chameleon" in the tumor. Malignant lymphoma often occurs in young and strong years, and the cause of the disease is unknown so far.
Penicillium anthrone is an anthraquinone organic compound produced by secondary metabolism of fungi, and is first obtained from Penicillium anthrone A in 2002Penicillium thomiiTo date, over a decade has passed. The compounds are reported to date as 2, each of which is penam A, B and all of which are 2-4' linked. The compound has obvious inhibition on tumor cells, and is an ideal raw material for developing antitumor drugs or tumor cell proliferation inhibitors. But the research on the antitumor activity of their enantiomers is still blank.
The present inventors have studied and found that Penicillium oxalicum (Penicillium oxalicum) IBPT-6, (deposited at the chinese type culture collection on 25.12.2013, address: wuhan, Wuhan university, the accession number is: CCTCC NO: m2013714), and the active ingredients thereof were studied. Researches show that the penicillium anthrone compound has anti-human lymphoma activity, and no report of the proliferation inhibition activity of the compound on human lymphoma cells exists at present, so that no related medicine exists in the market.
Disclosure of Invention
The invention aims to provide iso-Penicillium xanthone A derived from penicillium oxalicum and application thereof in lymphoma. The compound has effects of inhibiting lymphoma cell proliferation, and resisting human lymphoma. The structural formula is as follows:
the preparation method of the compound is to culture penicillium oxalicum (A)Penicillium oxalicum) IBPT-6, obtaining fermented mycelium, and separating and purifying the compound from the mycelium. The method comprises the following specific steps:
1 fermentation production
Culturing microorganism by conventional method, collecting Penicillium oxalicum (B) ((B))Penicillium oxalicum) IBPT-6 is inoculated on a flat solid culture medium, cultured in an incubator at 28 ℃ for 2-3d, then inoculated in a fungus culture medium, statically cultured at 28 ℃ for 30 d, and filtered by a plurality of layers of gauze to obtain mycelium and fermentation liquor; the fungus culture medium comprises the following components: 10.0 g of glucose, 20.0g of maltose, 20.0g of mannitol, 10.0 g of monosodium glutamate, 3.0 g of yeast extract, 15.0 g of NaCl and KH2PO40.5 g、MgSO4·7H2O0.3 g and ultrapure water were added to the reaction solution to a constant volume of 1L.
2 obtaining of extract
The mycelium and the fermentation broth were separated with gauze. Continuously performing ultrasonic wall breaking on the mycelia for 3 times by using an acetone solution (containing 20-30% of water), and filtering to remove residues to obtain a crude extract of the mycelia containing acetone and water. Concentrating under reduced pressure to remove acetone to obtain water solution of crude extract, extracting with ethyl acetate at volume ratio of the water solution to ethyl acetate of 1:2 for 3 times to obtain ethyl acetate crude extractive solution, concentrating, and evaporating to obtain mycelium extract 36.5 g.
3 separation and purification of Compound
The mycelium extract is mixed with 100-plus 200-mesh silica gel, and the mixture is mixed with petroleum ether: dichloromethane: methanol is used as gradient eluent, and decompression silica gel chromatographic column chromatography is carried out. The components A-E are separated by simple thin-layer chromatography analysis, combination and separation. Component C (12)7 g) with dichloromethane: methanol =1:2 as gradient eluent, performing gel column chromatography (Sephadex LH-20), and mixing to obtain four subfractions C after thin layer chromatography1-C4. Subfraction C3(4.9 g) by semi-preparative liquid chromatography (type 1010 ODS-A, 10X 250 mm, 5 μm): the isolation flow was 5 mL/min and the mobile phase was 55% acetonitrile with 0.1% TFA to give the indicated compound (510mg, t)R22.8 min)。
Said penicillium oxalicum (A), (B)Penicillium oxalicum) IBPT-6, which has been deposited at the China center for type culture Collection on 25.12.2013, address: wuhan, Wuhan university, the accession number is: CCTCC NO: m2013714.
The invention also comprises the application of the compound in preparing medicaments for inhibiting human lymphoma cell proliferation and the application of the compound in preparing medicaments for resisting human lymphoma.
The invention has the following remarkable advantages: researches show that the penicillium anthrone compound has remarkable activity of inhibiting human lymphoma cell proliferation, and no report of the compound on the activity of inhibiting human lymphoma cell proliferation exists at present, so that no medicine related to the activity is found in the market.
Drawings
FIG. 1 major COSY, HMBC and NOE signals of Iso-Penicillixanthone A.
Detailed Description
The chemical structures of the compounds referred to in the examples below:
EXAMPLE 1 fermentative production and isolation purification of the Compound
1 fermentation production
Fermentation culture of producing bacteria: taking Penicillium oxalicum (B) according to a conventional method for culturing microorganismsPenicillium oxalicum) IBPT-6 (deposited in the China center for type culture Collection on 25.12.2013, address: wuhan, Wuhan university, the accession number is: CCTCC NO: m2013714) in proper amount, inoculating on a flat solid culture mediumCulturing at 28 deg.C for 2-3 d.
Taking flat plate to culture 2-3d penicillium oxalicum (Penicillium oxalicum) An appropriate amount of IBPT-6 was inoculated into a container containing 400 mL of culture broth [ composition of culture broth (g/L): 10.0 parts of glucose, 20.0 parts of maltose, 20.0 parts of mannitol, 10.0 parts of monosodium glutamate, 3.0 parts of yeast extract, 15.0 parts of NaCl and KH2PO40.5、MgSO4·7H2O0.3, and the volume of ultrapure water is up to 1L]And performing static culture at 28 ℃ for 30 days to obtain mycelium and fermentation liquor.
2 obtaining of extract
The mycelium and the fermentation broth were separated with gauze. Continuously performing ultrasonic wall breaking on the mycelia for 3 times by using an acetone solution (containing 20-30% of water), and filtering to remove residues to obtain a crude extract of the mycelia containing acetone and water. Concentrating under reduced pressure to remove acetone to obtain water solution of crude extract, extracting with ethyl acetate at volume ratio of 1:2 for 3 times to obtain ethyl acetate crude extractive solution, and concentrating under reduced pressure to near dry to obtain mycelium extract 36.5 g.
3 separation and purification of Compound
The mycelium extract is mixed with 100-plus 200-mesh silica gel, and the mixture is mixed with petroleum ether: dichloromethane: methanol is used as gradient eluent, and decompression silica gel chromatographic column chromatography is carried out. By simple thin layer chromatography, combining, and separating into components A-E. Component C (12.7 g) was purified in dichloromethane: methanol =1:2 as gradient eluent, performing gel column chromatography (Sephadex LH-20), and mixing to obtain four subfractions C after thin layer chromatography1-C4. Subfraction C3(4.9 g) by semi-preparative liquid chromatography (type 1010 ODS-A, 10X 250 mm, 5 μm): the isolation flow was 5 mL/min and the mobile phase was 55% acetonitrile with 0.1% TFA to give the indicated compound (510mg, t)R22.8 min)。
Compound (I) is yellow powder at room temperature, [ α ]]20 D+ 105.6° (c 1, pyridine); [α]20 D+ 3.1°(c 1, Me2CO) high resolution electrospray mass spectrometry HRESI-MS at m/z: 661.1550 shows molecular ion peak [ M + Na]+(calcd for C32H30NaO14661.1533); molecular weight at 638, estimated from spectral informationSub-formula is C32H30O14。1H and13the C-NMR data are shown in Table 1, and the main COSY, HMBC and NOE signals are shown in FIG. 1.
Of the compounds of Table 11H and13C-NMR data (500 MHz)1H and 126 MHz13C, in DMSO-d 6 )
Example 2 in vitro testing of antitumor Activity
1 Experimental sample and experimental method
Preparing a solution of a sample to be detected: the test sample was the purified compound isolated and purified in example 1. Precisely weighing a proper amount of sample, preparing a 100 mM mother solution by DMSO, filtering and sterilizing by a filter membrane, and storing at-20 ℃ for later use. The proportion of DMSO is controlled below 1 per mill.
Taking out frozen cell strain from liquid nitrogen, rapidly melting in 37 deg.C water bath, centrifuging at 1200 rpm for 5 min, discarding frozen solution, adding 1 mL culture medium, pumping into culture flask, adding 5 mL fresh DMEM or RPMI 1640 culture medium, gently shaking to uniformly suspend cells in culture medium, standing at 37 deg.C and 5% CO2Cultured in an incubator. When the cell density reaches about 90%, passage is carried out, old culture medium is removed, PBS is washed for 2 times, 300 mu L of pancreatin is added (the pancreatin can cover the bottom of the bottle), the cell is digested in an incubator at 37 ℃ until the cell becomes round and is about to fall off, the culture medium containing 10% fetal calf serum is added to stop the digestion, the cell is divided into 2-3 new culture bottles after being blown and evenly mixed, and the culture medium is supplemented to ensure that the cell continues to grow in the incubator.
Cell proliferation inhibitory Activity test method (WST-1 method)
The activity evaluation of the anti-tumor cells adopts a WST-1 kit detection method, and the cell concentration is adjusted to be 3 multiplied by 10 after the tumor cells in the logarithmic growth phase are digested4a/mL single cell suspension, 100 μ L of the cell suspension was mixed and inoculated into a 96-well plate, 5 replicate wells per concentration. Then placing at 37 ℃ and 5% CO2The culture was carried out overnight in an incubator. Removing supernatantSolution, drug diluted to different concentrations with medium was added to the corresponding 96-well plate, and control group was added with medium containing the same amount of DMSO. After culturing for 72 h, adding 10 mu L of WST-1 solution into each well, incubating for 2 h at 37 ℃, gently shaking and uniformly mixing, and measuring the light absorption value at 450 nm by using a microplate reader. The mean OD value for 5 wells was calculated and calculated according to the formula: cell proliferation inhibition rate = (OD control group-OD blank group)/(OD experimental group-OD blank group) × 100% the proliferation inhibition rate of each concentration of drug on tumor cells was calculated, and half inhibition rate IC was calculated using Graphpad prism5.0 software50。
2 results of the experiment
The results of the cell proliferation inhibitory activity test are shown in Table 2.
TABLE 2 inhibitory Activity of Compounds on human lymphoma cell proliferation
3 conclusion
The compound has good anti-tumor activity on human lymphoma cells. Can be used for preparing lymphoma cell proliferation inhibiting medicine or antitumor medicine for lymphoma research.
Claims (3)
1. Compound (I)Characterized in that the compound is prepared by the following method: fermented Penicillium oxalicum (Penicillium oxalicum) IBPT-6, obtaining a fermentation product, and then separating and purifying the fermentation product to obtain the compound; wherein said Penicillium oxalicum (A), (B)Penicillium oxalicum) IBPT-6, which has been deposited at the China center for type culture Collection on 25.12.2013, address: wuhan, Wuhan university, the accession number is: CCTCC NO: and M2013714.
2. Use of a compound according to claim 1 for the preparation of a medicament for inhibiting the proliferation of lymphoma cells.
3. Use of a compound according to claim 1 for the preparation of an anti-lymphoma medicament.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811474254.1A CN110922382A (en) | 2018-12-04 | 2018-12-04 | iso-Penicillium xanthone A from penicillium oxalicum and application in lymphoma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811474254.1A CN110922382A (en) | 2018-12-04 | 2018-12-04 | iso-Penicillium xanthone A from penicillium oxalicum and application in lymphoma |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110922382A true CN110922382A (en) | 2020-03-27 |
Family
ID=69856460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811474254.1A Pending CN110922382A (en) | 2018-12-04 | 2018-12-04 | iso-Penicillium xanthone A from penicillium oxalicum and application in lymphoma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110922382A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3002761A1 (en) * | 1979-01-30 | 1980-07-31 | Asahi Chemical Ind | NEW SECALONIC ACIDS METHOD FOR THE PRODUCTION AND USE THEREOF |
JP2001031564A (en) * | 1999-05-19 | 2001-02-06 | Mitsubishi Chemicals Corp | Telomerase inhibitor |
CN107353274A (en) * | 2017-06-17 | 2017-11-17 | 福州大学 | Come from the secalonic acid I of penicillium oxalicum and prepare the application of anti-human oesophagus cancer drug |
-
2018
- 2018-12-04 CN CN201811474254.1A patent/CN110922382A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3002761A1 (en) * | 1979-01-30 | 1980-07-31 | Asahi Chemical Ind | NEW SECALONIC ACIDS METHOD FOR THE PRODUCTION AND USE THEREOF |
US4424373A (en) * | 1979-01-30 | 1984-01-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Secalonic acids |
JP2001031564A (en) * | 1999-05-19 | 2001-02-06 | Mitsubishi Chemicals Corp | Telomerase inhibitor |
CN107353274A (en) * | 2017-06-17 | 2017-11-17 | 福州大学 | Come from the secalonic acid I of penicillium oxalicum and prepare the application of anti-human oesophagus cancer drug |
Non-Patent Citations (5)
Title |
---|
GUANGWEI WU,ET AL.: "Structure-based discovery of cytotoxic dimeric tetrahydroxanthones as potential topoisomerase I inhibitors from a marine-derived fungus", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
LI CHEN,ET AL.: "Isolation of 4,4′-bond secalonic acid D from the marine-derived fungus Penicillium oxalicum with inhibitory property against hepatocellular carcinoma", 《THE JOURNAL OF ANTIBIOTICS》 * |
TAMAM EL-ELIMAT,ET AL.: "Biosynthetically Distinct Cytotoxic Polyketides from Setophoma terrestris", 《EUROPEAN J ORG CHEM.》 * |
杨小姣 等: "中华剑角蝗内生真菌Penicillium oxalicum次级代谢产物Secalonic acid A的分离及毒性实验研究", 《三峡大学学报(自然科学版)》 * |
江蔚新 等: "丰肉结海绵相关青霉菌HLS-216次级代谢产物研究", 《药学研究》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107298671B (en) | Selenolonic acid H from penicillium oxalicum and application thereof in preparing medicine for resisting human colon cancer | |
CN107353274B (en) | Selenolonic acid I from penicillium oxalicum and application thereof in preparation of human esophageal cancer resistant medicine | |
CN107298672B (en) | Application of seclenic acid I derived from penicillium oxalicum in preparation of anti-human colon cancer drugs | |
CN107298670B (en) | Application of medicine derived from penicillium oxalicum seclenum ketonic acid H in preparation of anti-human oral epidermoid carcinoma medicines | |
CN107485607B (en) | Application of seclenic acid H derived from penicillium oxalicum in preparation of human esophageal cancer resistant medicine | |
CN107298669B (en) | Selenolonic acid I from penicillium oxalicum and application of medicine for resisting human oral epidermoid carcinoma | |
CN110407792B (en) | Secalonic acid J compound derived from penicillium oxalicum and preparation method thereof | |
CN111499649B (en) | Benzodifuranone compound with anti-tumor activity, preparation method and application thereof | |
CN110669800A (en) | Application of iso-Penicillium xanthone A from Penicillium oxalicum and adriamycin resistance | |
CN110627763A (en) | iso-Penicillium xanthone A from Penicillium oxalicum and application of anti-cisplatin drug resistance | |
CN109106702A (en) | Derived from application of 4-4 ' the isomerization secalonic acid D in terms of colon cancer of penicillium oxalicum | |
CN109134416B (en) | Application of seclenic acid H derived from penicillium oxalicum in preparation of human cervical cancer drugs | |
CN112358516A (en) | Application of diosmetin (4-O-methyl) glucoside compound in preparation of lipid-lowering drugs | |
CN110923278A (en) | iso-Penicillium xanthone A from penicillium oxalicum and application in lung cancer | |
CN110327328A (en) | Application of 25 β--23 β of the secondary cyclobutenyl-isobutyl acyloxy mibemycin derivative in antitumor | |
CN109776477A (en) | Iso-Penicillixanthone A and anti-vincristine drug resistance application derived from penicillium oxalicum | |
CN110407794B (en) | Selenolonic acid K derived from penicillium oxalicum and application thereof in inhibiting cancer cell proliferation | |
CN110407797B (en) | Secalonic acid K compound derived from penicillium oxalicum and preparation method thereof | |
CN102030753A (en) | Prenylated indole alkaloids and preparation method and application thereof | |
CN109134417B (en) | Selenolonic acid I from penicillium oxalicum and application of medicine for resisting human cervical cancer | |
CN109776478B (en) | iso-Penicillium xanthone A from penicillium oxalicum and application in cervical cancer | |
CN110922382A (en) | iso-Penicillium xanthone A from penicillium oxalicum and application in lymphoma | |
CN110917185A (en) | iso-Penicillium xanthone A from penicillium oxalicum and application in aspect of breast cancer | |
CN110922383A (en) | iso-Penicillium xanthone A from Penicillium oxalicum and its application in gastric cancer | |
CN110922378A (en) | iso-Penicillium xanthone A from penicillium oxalicum and application in nasopharyngeal carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200327 |